Table 1 Comparison of radiological assessment criteria

From: Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients

 

RECIST 1.1 (Eisenhaueret al, 2009)

irRC (Wolchoket al, 2009)

CHOI (Choiet al, 2004, 2007)

mCHOI (Nathanet al, 2010)

Method

Sum of the longest diameters (unidimensional) of index lesions

Sum of the products of the two largest perpendicular diameters (SPD) of all index lesions (5 lesions per organ, up to 10 visceral lesions and 5 cutaneous lesions) is calculated. Subsequently, on each scan, the SPD of the index lesions and of new, measurable lesions (⩾5 × 5 mm; up to 5 new lesions per organ: 5 new cutaneous lesions and 10 visceral lesions) are added to provide total tumour burden

Changes in tumour size (sum of the longest diameters) and changes in tumour density of index lesions

Changes in tumour size (sum of the longest diameters) and changes in tumour density of index lesions

Complete response

Disappearance of all target lesions or nodal short axis diameter <10 mm on follow-up

Disappearance of all lesions in two consecutive observations not <4 weeks apart

Disappearance of all lesions

No new lesions

Disappearance of all target lesion

Partial response

>30% decrease in sum of longest diameter (LD)

>50% decrease in the burden of tumour compared with baseline in two observations at least 4 weeks apart

Decrease in size of >10% or a >15% decrease in tumour density (HU). No new lesions

Decrease in size of >10% and >15% decrease in tumour density (HU). No new lesions

Progressive disease

>20% increase in sum of LD taking as reference the smallest LD recorded and at least 5 mm increase or new lesion

Increase in tumour burden >25% relative to the minimum recorded tumour burden in two consecutive observations, at least 4 weeks apart

>10% increase in tumour size and does not meet criteria of PR by tumour density. New lesions

>10% increase in tumour size and does not meet criteria of PR by tumour density. New lesions

Stable disease

Neither PR nor PD

Neither of the above

Does not meet criteria of CR, PR or PD

Does not meet criteria of CR, PR or PD

  1. Abbreviations: CR=complete response; irRC=immune-related response criteria; mCHOI=modified CHOI; PD=progressive disease; PR=partial response; RECIST=response evaluation criteria in solid tumors.